50 completed, 10 terminated, 8 unknown, 7 active not recruiting. 47 Phase 2, 39 Phase 1, 10 Phase 3, 2 Early Phase 1, 1 Not applicable.
Follow Astex Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Intervention in High Risk CCUS Inqovi - Clonal Cytopenia of Undetermined Significance, Cytopenia | Early Phase 1 | Recruiting | Lachelle D. Weeks, MD, PhD | 108 | 2025-02-07 | 2026-04-23 |
| A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation ASTX727, Donor Lymphocyte Infusion - Allogeneic Stem Cell Transplantation | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2024-07-01 | 2026-05-15 | |
| A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) ASTX727, Venetoclax - Acute Myeloid Leukemia | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 40 | 2024-03-07 | 2026-09-04 |
| A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS) Decitabine/Cedazuridine, Magrolimab - Myelodysplastic Syndromes | Phase 2 | Terminated | Astex Pharmaceuticals, Inc. | 2 | 2023-06-27 | 2024-10-02 |
| A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE) SNDX-5613, Venetoclax, ASTX727 - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-10-14 | 2026-09-23 |
| A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS Bisantrene Dihydrochloride (high dose), Bisantrene Dihydrochloride (low dose), Cytarabine Hydrochloride - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 1 | Withdrawn | Racura Oncology Ltd | 2022-07-29 | 2023-10-03 | |
| ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab ASTX660, Pembrolizumab - Advanced Cancer, Cervical Cancer | Phase 1 | Active not recruiting | Institute of Cancer Research, United Kingdom | 61 | 2022-03-02 | 2026-06-25 |
| Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer Tolinapant, Radiation Therapy - Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma | Early Phase 1 | Active not recruiting | Emory University | 10 | 2022-02-17 | 2026-08-21 |
| Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO) ASTX727, Itacitinib, Ruxolitinib - MDS/MPN | Phase 1 / Phase 2 | Recruiting | Michael Savona | 94 | 2021-11-24 | 2026-04-21 |
| ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase Dasatinib, Decitabine and Cedazuridine - Chronic Phase Chronic Myelogenous Leukemia, Philadelphia Chromosome Positive | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2021-10-21 | 2026-10-02 |
| Thorough QT Assessment of Cedazuridine in Healthy Subjects Cedazuridine, Placebo, Moxifloxacin - Healthy Volunteers | Phase 1 | Completed | Astex Pharmaceuticals, Inc. | 36 | 2021-07-01 | 2024-08-02 |
| ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients ASTX727, Donor Lymphocyte Infusions - MDS, AML | Phase 2 | Completed | Groupe Francophone des Myelodysplasies | 57 | 2021-06-22 | 2025-05-14 |
| Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Decitabine and Cedazuridine, Venetoclax - Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 52 | 2021-01-19 | 2026-09-04 |
| A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms TAS1553 - Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 1 | Terminated | Astex Pharmaceuticals, Inc. | 20 | 2020-12-21 | 2024-08-02 |
| A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029 ASTX029 - Healthy Volunteers | Phase 1 | Completed | Astex Pharmaceuticals, Inc. | 18 | 2020-07-23 | 2024-08-02 |
| Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers ASTX660 - Healthy Volunteer | Phase 1 | Completed | Astex Pharmaceuticals, Inc. | 21 | 2020-07-20 | 2024-08-02 |
| A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) ASTX660, ASTX727 - Acute Myeloid Leukemia | Phase 1 | Terminated | Astex Pharmaceuticals, Inc. | 68 | 2020-06-12 | 2024-08-02 |
| A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam ASTX660, Midazolam, Itraconazole - Healthy Volunteer | Phase 1 | Completed | Astex Pharmaceuticals, Inc. | 36 | 2020-05-20 | 2024-08-02 |
| Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer Talazoparib, ASTX727 - Metastatic Breast Cancer, Triple Negative Breast Cancer | Phase 1 | Completed | Kathy Miller | 34 | 2020-04-01 | 2024-03-22 |
| A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1 Ipilimumab plus nivolumab plus guadecitabine, Ipilimumab plus nivolumab - Melanoma, Non Small Cell Lung Cancer | Phase 2 | Unknown | Italian Network for Tumor Biotherapy Foundation | 184 | 2020-03-01 | 2020-01-31 |
Showing 20 of 85. Sign in to see all of them.
Leukemia, Myeloid, Acute (13) · Myelodysplastic Syndromes (11) · Leukemia, Lymphocytic, Chronic, B-Cell (8) · Leukemia, Myelomonocytic, Chronic (8) · Leukemia (6) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Lymphoma (5) · Lymphoma, Non-Hodgkin (5) · Carcinoma, Non-Small-Cell Lung (4) · Neoplasms (4) · Pancreatic Neoplasms (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Hodgkin Disease (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3)
decitabine and cedazuridine drug combination (18) · guadecitabine (16) · rubitecan (12) · Decitabine (10) · Pentostatin (10) · ASTX-660 (5) · Cyclophosphamide (5) · Rituximab (5) · cedazuridine (5) · (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (4) · amuvatinib (4) · pembrolizumab (4) · Carboplatin (3) · Gemcitabine (3) · venetoclax (3)
United States (72) · Canada (19) · United Kingdom (10) · France (7) · Italy (7) · Spain (7) · South Korea (5) · Denmark (4) · Germany (4) · Japan (4) · Poland (4) · Austria (3) · Belgium (3) · Czechia (3) · Hungary (3)
Show-Li Sun, MD (6) · Lawrence A. Romel, MS (3) · Amber Gibson, DO (1) · Anna Maria Di Giacomo, MD (1) · Anna Maria Di Giacomo, PhD,MD (1) · Betul Oran, MD (1) · Craig Reynolds, MD (1) · Daniel M. Sullivan, M.D. (1) · Daniela Matei, MD (1) · David Jacobsohn, MD, MSc (1) · Elias Jabbour (1) · Farhad Ravandi-Kashani, MD (1) · Felipe Samaniego, MD (1) · Ghayas Issa, MD (1) · Gregory Berk, MD (1)
PMID 27750483, PMID 16882708, PMID 17514743, PMID 19654407, PMID 19745067, PMID 20187101, PMID 23178951, PMID 23260600, PMID 23790798, PMID 24072436, PMID 24355079, PMID 24849582, PMID 26296954, PMID 26376958, PMID 27156227, PMID 28445481, PMID 30926081, PMID 31060979, PMID 31331399, PMID 31831561, PMID 32285126, PMID 33289590, PMID 35671108, PMID 35717027, PMID 36934257, PMID 37276510, PMID 37739939, PMID 38135371, PMID 38231126, PMID 38312102, PMID 38316133, PMID 40091844, PMID 40784355, PMID 41621809, PMID 42272166
2015 (1), 2018 (1), P30CA008748 (1), P30CA014089 (1), P30CA060553 (1), P30CA138292 (1)